Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

Psoriasis patients use social networks. Here’s why you shoul...

What do psoriasis patients discuss online? Brian Loew explores, and highlights the significance of these conversations with regards to the healthcare industry. About 8 in 10 psoriasis patients who use social networks say they do so because they want to learn how others manage their psoriasis...

Articles

Can we market non-commercially viable orphan drugs?

Oliver Timmis questions whether the pharma industry can market non-commercially viable orphan drugs, as our rare disease focus continues. Rare diseases were historically neglected by the pharmaceutical industry, because it was not commercially...

Articles

Contracts in clinical trials in emerging region: Asia Pacifi...

Tarun Pandotra explores the sometimes forgotten, but extremely important, aspect of clinical trials: the contract, including negotiations, budget and signing. There are many things to plan when considering to conduct a clinical trial. Not so long ago contract was one…

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital